Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.55 |
| ▸ | FABP5 | Q01469 | 3/20 | 0.54 |
| ▸ | FABP7 | O15540 | 2/20 | 0.54 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.51 |
| ▸ | CA1 | P00915 | 1/20 | 0.50 |
| ▸ | CA2 | P00918 | 1/20 | 0.50 |
| ▸ | HTR2A | P28223 | 1/20 | 0.44 |
| ▸ | CASP3 | P42574 | 2/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29783591 | 1.00 | KMT2A (0.55) | KMT2AFABP5FABP7EPHX2CA1 | |
| SCHEMBL44676 | 0.85 | KMT2A (0.58) | KMT2AFABP5FABP7EPHX2CA1 | |
| SCHEMBL15981181 | 0.85 | KMT2A (0.58) | KMT2AFABP5FABP7EPHX2CA1 | |
| SCHEMBL29381061 | 0.83 | FABP5 (0.59) | KMT2AFABP5FABP7EPHX2CA1 | |
| SCHEMBL12016740 | 0.83 | KMT2A (0.56) | KMT2AFABP5FABP7EPHX2CA1 | |
| SCHEMBL29901230 | 0.83 | FABP5 (0.59) | KMT2AFABP5FABP7EPHX2CA1 | |
| SCHEMBL30667581 | 0.83 | KMT2A (0.56) | KMT2AFABP5FABP7EPHX2CA1 | |
| SCHEMBL2782675 | 0.83 | KMT2A (0.56) | KMT2AFABP5FABP7EPHX2CA1 | |
| SCHEMBL44677 | 0.83 | FABP5 (0.59) | KMT2AFABP5FABP7EPHX2CA1 | |
| SCHEMBL13044481 | 0.82 | KMT2A (0.52) | KMT2AFABP5FABP7EPHX2CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024137502-A2 | PNU ANTHRACYCLINE-DERIVED LINKER-PAYLOADS, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF | MERCK SHARP & DOHME LLC (US) | 2024-06-27 | — | — | WO | disclosed |
| US-8748570-B2 | Insulin analogues | SYNGENE LIMITED (AU) | 2014-06-10 | — | — | US | disclosed |
| US-20120225811-A1 | INSULIN ANALOGUES | POLYCHIP PHARMACEUTICALS PTY LTD (AU) | 2012-09-06 | — | — | US | disclosed |
| EP-2366704-A1 | Inhibitors of serine proteases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-09-21 | — | — | EP | disclosed |
| US-20080234464-A1 | Compound Having Amino Acid Residue or Peptide Residue and Process for Producing the Same | CREDIA JAPAN CO., LTD. (JP) | 2008-09-25 | — | — | US | disclosed |
| US-7339023-B2 | Partial peptide mimetics and methods | REGENTS OF THE UNIVERSITY OF MINNESOTA (US) | 2008-03-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120225811-A1 | INSULIN ANALOGUES | IAPP, INSR, GPR119 | KMT2A 2420/4885FABP5 161/4885FABP7 198/4885 |
| US-20080234464-A1 | Compound Having Amino Acid Residue or Peptide Residue and Process for Producing the Same | NGLY1, ELOVL6, ELOVL1 | KMT2A 1414/4885FABP5 188/4885FABP7 261/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.